Q32 Bio

eczema atopic dermatitis Black African American patient skin of color

Q32's stock plunges in wake of anti-IL-7R antibody's eczema fail

Q32 still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but investors appear unconvinced.

James Waldron Dec 11, 2024 8:25am

J&J's medtech chief out the door—Chutes & Ladders

Oct 27, 2023 9:30am

Maxwell Biosciences taps 3 leaders—Chutes & Ladders

Sep 23, 2022 9:30am

Lilly's longtime manufacturing chief to retire—Chutes & Ladders

Mar 12, 2021 10:13am

Ex-Intercept CMO Campagna lands at Q32

Mar 9, 2021 8:45am

Q32 Bio banks $60M as it ramps up 'immune rebalancing' programs

Oct 29, 2020 9:45am